NANOLOGICA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.6 SEK | -1.75% |
|
-1.06% | -46.15% |
| 26/04 | Nanologica AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 11/04 | Nanologica's New COO to Take Office in May | MT |
| Sales 2024 * | 61.4M 5.65M 472M | Sales 2025 * | 168M 15.51M 1.29B | Capitalization | 247M 22.79M 1.9B |
|---|---|---|---|---|---|
| Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 4.03 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.47 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 16 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 82.86% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.75% | ||
| 1 week | -1.06% | ||
| Current month | -17.16% | ||
| 1 month | -16.17% | ||
| 3 months | -21.57% | ||
| 6 months | -46.41% | ||
| Current year | -46.15% |
1 week
4.49
6.00
1 month
4.496.96
Current year
4.4910.60
1 year
4.4913.70
3 years
4.4917.45
5 years
4.4920.00
10 years
2.6021.90
| Managers | Title | Age | Since |
|---|---|---|---|
Andreas Bhagwani
CEO | Chief Executive Officer | 49 | 01/11/01 |
Eva Osterman
DFI | Director of Finance/CFO | 53 | 01/17/01 |
| Investor Relations Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 66 | 01/12/01 | |
| Director/Board Member | 64 | 01/21/01 | |
Anders Rabbe
BRD | Director/Board Member | 54 | 01/20/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/24/02 | 5.6 | -1.75% | 25,459 |
| 30/24/30 | 5.7 | +1.06% | 11,823 |
| 29/24/29 | 5.64 | +2.55% | 26,995 |
| 26/24/26 | 5.5 | -1.43% | 483,112 |
| 25/24/25 | 5.58 | +0.72% | 31,352 |
Delayed Quote Nasdaq Stockholm, May 02, 2024 at 08:36 pm IST
More quotes
Nanologica AB (publ) is a Sweden-based materials development company. The Company specializes in developing nanoporous materials from nanoporous silica (silicon dioxide) for a variety of applications, ranging from purification to pharmaceutical excipients. The Company's core competency has been developed and expanded in two areas of application, in particular: Drug Delivery and Chromatography, a technology used for the separation and purification of products on the market and in development. The Company's Drug Delivery sector operates within a niche domain of nanocarriers. Nanologica AB (publ)âs drug delivery technology is aimed on absorption of the medicine by the body for drugs that are poorly soluble in water.
Sector
Commodity Chemicals
Calendar
05/07/2024
- Q2 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -46.15% | 22.95M | |
| +3.63% | 40.24B | |
| -19.34% | 22.02B | |
| -13.51% | 13.39B | |
| -10.91% | 9.97B | |
| -10.36% | 9.47B | |
| +5.92% | 7.7B | |
| +12.15% | 7B | |
| -26.77% | 5.56B | |
| -29.83% | 3.28B |
- Stock Market
- Equities
- NICA Stock
